TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21281406
Drug: Mebendazole (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (500 mg single dose)
Study: 9497178
Drug: 10.2 g
Normalized name: IODINE 10.2 g in 1 L TOPICAL SOLUTION [Proteat]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.2 g psyllium seed husk (PSH)/d
Study: 9497178
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 g PSH/d)
Study: 9497178
Drug: 3.4 g
Normalized name: psyllium 3.4 g oral wafer
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.4 g psyllium seed husk (PSH)/d
Study: 9497178
Drug: 6.8 g
Normalized name: Veltassa 16.8 GM Powder for Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.8 g psyllium seed husk (PSH)/d
Study: 7710954
Drug: Melatonin (MLT)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MLT) 20 mg orally daily starting 7 days before tamoxifen (TMX)
Study: 7710954
Drug: Tamoxifen (TMX)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TMX) 20 mg orally daily
Study: 17879543
Drug: Qingbi Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingbi Tablet (Chinese herbal preparation)
Study: 7851263
Drug: Intensified conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified conventional treatment
Study: 26444986
Drug: Luseogliflozin 20
Normalized name: luseogliflozin
DrugBank: Luseogliflozin (DB12214)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Luseogliflozin 20 mg
Study: 22287376
Drug: 2 mL
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL 0.25% bupivacaine with epinephrine 1:100,000 (BP)
Study: 19695030
Drug: Olmesartan 40
Normalized name: HCTZ 25/OLMESARTAN 40MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 40 mg administered at morning
Study: 15581208
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg with alcohol
Study: 15581208
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) 300 mg without alcohol
Study: 15891633
Drug: Radiofrequency tympanostomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency tympanostomy with topical mitomycin C application (Group C)
Study: 11982640
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a single-strain Leishmania amazonensis killed promastigote vaccine plus a half dose of meglumine antimoniate.
Study: 11982640
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus half dose of meglumine antimoniate.
Study: 7461567
Drug: Benzbromarone-citrate combination
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzbromarone-citrate combination (Harolan)
Study: 26847527
Drug: Physiotherapeutic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physiotherapeutic intervention including daily training program with movements to increase chest flexibility, breathing exercises, and relaxation sessions.
Study: 25756412
Drug: Inhaled volatile
Normalized name: Peppermint volatile oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled volatile anesthetic agents (isoflurane or sevoflurane) (n = 67)
Study: 23815747
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block (20 mL of either 0.375% ropivacaine or 0.3% levobupivacaine)
Study: 23815747
Drug: Control (epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (epidural morphine 2 mg)
Study: 21573941
Drug: Red pepper
Normalized name: Red pepper
DrugBank: Red pepper (DB14759)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red pepper (150 mg of red pepper powder, 4 pills/day for 6 weeks)
Study: 1547685
Drug: GLP‐I‐(7‐37) infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐I‐(7‐37) infusion concurrent with a standard meal
Study: 1547685
Drug: GLP‐I‐(7‐37) infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐I‐(7‐37) infusion
Study: 30140006
Drug: LPS injection
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS injection
Study: 9456419
Drug: Retrobulbar injection
Normalized name: LIDOCAINE HYDROCHLORIDE 40 mg in 1 mL RETROBULBAR INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrobulbar injection of lidocaine 4%
Study: 7943774
Drug: Midazolam 0.1
Normalized name: midazolam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.1 mg/kg (M high)
Study: 7943774
Drug: Lorazepam 0.1
Normalized name: lorazepam 0.1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 0.1 mg/kg (L high)
Study: 3285835
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg torasemide
Study: 21914281
Drug: Shenfu (SF)
Normalized name: light green SF yellowish
DrugBank: Light green SF yellowish (DB11183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu (SF) injection administered by peripheral intravenous infusion at initially 0.2 ml/kg and then 0.8 ml×kg(‐1)×h(‐1) until the end of operations
Study: 21914281
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered similarly to Group S
Study: 17468908
Drug: D-Stat Dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Stat Dry bandage as an adjunct to manual compression
Study: 8076711
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (30 g/day for 3 days prior to each course of chemotherapy)
Study: 19544555
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation
Study: 29545253
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion of bone marrow-derived mononuclear cells
Study: 9347199
Drug: Ethanol infusion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol infusion
Study: 2666484
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (TS) patch
Study: 27707817
Drug: evolocumab 140
Normalized name: evolocumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolocumab 140 mg
Study: 27707817
Drug: evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolocumab 420 mg
Study: 22751965
Drug: Individual withdrawal
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual withdrawal with restricted symptomatic medication and prophylactics from Day 1 (Group A)
Study: 22751965
Drug: Two-month drug-free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-month drug-free period with multidisciplinary education in groups (Group B)
Study: 11273876
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (15 mg intravenously three times weekly)
Study: 11273876
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (16.1 mg intravenously three times weekly)
Study: 2050174
Drug: Sublingual captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual captopril (25 mg)
Study: 2012448
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine (10 mg)
Study: 8247194
Drug: Sublingual prazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual prazosin (2 mg)
Study: 3930305
Drug: 6 capsules
Normalized name: TOBI Podhaler Weekly Kit, including 56 capsules (7 Blister Cards of 8 Capsules)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 capsules of carotenoids (10 mg beta‐carotene + 15 mg canthaxanthin per capsule)
Study: 3930305
Drug: 4 capsules
Normalized name: Jynarque 60 MG / 30 MG Carton Pack, 4 Blister Cards, 14 Capsules Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of carotenoids (10 mg beta‐carotene + 15 mg canthaxanthin per capsule)
Study: 3930305
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (4 and 6 capsules)
Study: 27776679
Drug: Quitline services
Normalized name: quinoline yellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quitline services (QL) including a motivational interview, 6 weeks of nicotine patches and gum, a referral to the QL, a booster call, and a quitline brochure.
Study: 12692805
Drug: Parenteral Nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Nutrition (PN)
Study: 8576291
Drug: Fluid therapy
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid therapy
Study: 22551742
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by a homeopath
Study: 15703163
Drug: Brachial intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brachial intra-arterial propranolol infusion in Gly(16)/Glu(27)
Study: 15703163
Drug: Brachial intra-arterial
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brachial intra-arterial propranolol infusion in Arg(16)/Gln(27)
Study: 9633736
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose intravenous methylprednisolone (IVMP)
Study: 9633736
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose intravenous methylprednisolone (IVMP)
Study: 8164314
Drug: Sebacate (6.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sebacate (6.6 g/h)
Study: 3356852
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of maternal IgG, IgA, or IgM antibodies to food at delivery
Study: 31119578
Drug: WBC count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WBC count modifications with elevated CRP (> 40 mg/L) or fever (> 38.5 °C) in infected patients
Study: 23568049
Drug: Low-volume polyethylene
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume polyethylene glycol plus bisacodyl (BPEG) 30 mL kg⁻¹ day⁻¹ plus oral bisacodyl 10 to 15 mg/day
Study: 23568049
Drug: Sennosides 2
Normalized name: sennosides 25 mg ORAL PILL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sennosides 2 mg kg⁻¹ day⁻¹
Study: 11587253
Drug: Calcium-fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-fortified milk supplement (3 L weekly in the first year)
Study: 11587253
Drug: Calcium-fortified milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-fortified milk supplement
Study: 8162479
Drug: Active low
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low level laser therapy (LLLT)
Study: 3144923
Drug: 2 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg.kg‐1 ketoprofen intravenously over 20 min
Study: 27916783
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (control group)
Study: 25448243
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections (SESIs) - 80mg of triamcinolone in normal saline
Study: 19500693
Drug: Virologic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Virologic response (levels of hepatitis B virus DNA below 10,000 copies/mL)
Study: 16885758
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of acetaminophen with codeine
Study: 16885758
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of acetaminophen with codeine
Study: 3139138
Drug: Intravenous salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous salbutamol (12 micrograms/min continuous infusion for 4 hours)
Study: 3139138
Drug: Nebulised salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulised salbutamol (5 mg nebulised on admission, plus two more 5 mg doses at 30 minutes and 2 hours)
Study: 16959472
Drug: ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (8 mg/day) combined with haloperidol (4-30 mg/day)
Study: 16959472
Drug: placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo combined with haloperidol (4-30 mg/day)
Study: 9348566
Drug: MMC/UFT (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC/UFT (20 mg of MMC sprinkled on the operating field, 6 mg/m2 of MMC intravenously on day 7 and monthly for 6 months, 400 mg/day of UFT orally for 1 year)
Study: 1316914
Drug: Percoll preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percoll preparation
Study: 8907672
Drug: Swim-up preparation
Normalized name: arched swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swim-up preparation
Study: 23028596
Drug: Pre-meal protein
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-meal protein drinks (PMPD) containing whey protein isolates (9 g protein)
Study: 19776051
Drug: Niacinamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacinamide (250 mg twice daily, titrated to 750 mg twice daily)
Study: 2071085
Drug: Nisoldipine 10
Normalized name: nisoldipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 10 mg/day
Study: 2071085
Drug: Diltiazem 3
Normalized name: diltiazem 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 3 x 60 mg/day
Study: 6404238
Drug: Cost analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost analysis with prophylactic antibiotics
Study: 25025992
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (CCBs) alone
Study: 22145610
Drug: ABT-594 150
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-594 150 μg
Study: 22145610
Drug: ABT-594 225
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-594 225 μg
Study: 22145610
Drug: ABT-594 300
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-594 300 μg
Study: 2735330
Drug: sucralfate 2
Normalized name: sucralfate 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 2 g twice daily for six weeks
Study: 2735330
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg at bedtime
Study: 2735330
Drug: pentagastrin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentagastrin 0.1 and 6.0 micrograms/kg/hour or histamine acid phosphate 4.0 and 40 micrograms/kg/hour (secretory stimulants)
Study: 30479044
Drug: Silymarin 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin 1% gel
Study: 28436572
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg delayed-release cysteamine bitartrate
Study: 25900350
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 mg administered at each session for five sessions over 1 week)
Study: 25900350
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered at each session for five sessions over 1 week)
Study: 23568575
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg)
Study: 18248656
Drug: Lubiprostone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone (all doses)
Study: 25664604
Drug: Oral octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral octreotide capsules (OOCs)
Study: 26551445
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri DSM 17938 (1 × 10 colony forming units daily)
Study: 22559011
Drug: Probiotic comprising
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic comprising two strains of lactobacilli and two strains of bifidobacteria, one capsule daily for 21 days
Study: 22559011
Drug: Matching placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, one capsule daily for 21 days
Study: 20484917
Drug: semi-standardised acupuncture
Normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: semi-standardised acupuncture plus rescue medication (cetirizine)
Study: 20484917
Drug: penetrating sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: penetrating sham acupuncture at non-acupuncture points plus rescue medication
Study: 20484917
Drug: rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: rescue medication alone for 8 weeks (standard treatment group)
Study: 16048984
Drug: Nelfinavir and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir and efavirenz (combination)
Study: 7537287
Drug: risperidone 8
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: risperidone 8 mg
Study: 7537287
Drug: clozapine 400
Normalized name: clozapine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clozapine 400 mg
Study: 7537287
Drug: risperidone (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: risperidone (both doses)
Study: 8445418
Drug: Carboplatin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboplatin (400 mg/m2)
Study: 2045855
Drug: Iproplatin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iproplatin (300 mg/m2)
Study: 7019932
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg emepronium bromide 3-times daily
Study: 21836528
Drug: TXA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA (10 mg/kg at induction followed by 1 mg/kg/h infusion)
Study: 9299382
Drug: Standard Stroop
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Stroop stimuli (e.g., the word 'RED' displayed in a green font)
Study: 24837060
Drug: Hypnobehavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnobehavioral therapy enhanced by energetic psychotherapy (HypEn)
Study: 23957874
Drug: Peer‐ and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer‐ and family‐based group therapies
Study: 1356175
Drug: Monthly pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly pulse cyclophosphamide for 6 months
Study: 3893195
Drug: Clonidine (3‐600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (3‐600 micrograms, six hourly)
Study: 3893195
Drug: Chlormethiazole (500‐1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole (500‐1000 mg, six hourly)
Study: 31470175
Drug: Curcumin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (3 g/day)
Study: 22313079
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g intravenous paracetamol intraoperatively
Study: 22313079
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g oral paracetamol 30 to 60 minutes preoperatively
Study: 30644983
Drug: Hematopoietic stem
Normalized name: Umbilical Cord Blood Hematopoietic Stem Cells
DrugBank: Umbilical Cord Blood Hematopoietic Stem Cells (DB15723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hematopoietic stem cell transplantation (HSCT) with cyclophosphamide (200 mg/kg) and antithymocyte globulin (6 mg/kg)
Study: 30644983
Drug: Disease-modifying therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-modifying therapy (DMT)
Study: 28901892
Drug: Anthocyanin (ACN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanin (ACN) supplementation (320 mg/d)
Study: 28901892
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) treatment
Study: 2148223
Drug: Isradipine SRO
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine SRO (5 mg) given at either 9 am or 9 pm
Study: 22195356
Drug: Valsartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (angiotensin II receptor blocker)
Study: 23448396
Drug: DHEA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (all doses)
Study: 20709233
Drug: Rimonabant 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimonabant 20 mg
Study: 15588275
Drug: Hormone levels
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone levels (FSH, LH, estradiol, progesterone) in patients with CFS
Study: 15588275
Drug: Hormone levels
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone levels in patients with high depression scores
Study: 31440031
Drug: Oral Yimaxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Yimaxin
Study: 31440031
Drug: Oral Utrogestan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Utrogestan
Study: 12664518
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg/kg
Study: 30283029
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg
Study: 26044602
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 mL (Control)
Study: 24112401
Drug: Collagenase clostridium
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase clostridium histolyticum (CCH) - investigational intralesional injection
Study: 8237624
Drug: Bendrofluazide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 2.5 mg daily
Study: 3614616
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg orally prior to sleep)
Study: 3614616
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg infusion throughout the night)
Study: 27046309
Drug: Cariprazine 2-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 2-4.5 mg/d
Study: 27046309
Drug: Cariprazine 1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 1-2 mg/d